


Disclosing material information

Date	18. May 20223
Name of the Listed Company	Gulf Pharmaceutical Industries PJSC
The Material Information	Licensing and Technology Transfer Agreement signed with Sunshine Lake Pharma, China for modern Insulin Glargine and Aspart
The expected effect of material information on the financial position and results of the company's business and operations	Julphar will invest in the technology transfer and required manufacturing capabilities to produce Insulin Glargine and Aspart at its manufacturing campus in Ras Al Khaimah. The products are expected to contribute positively to Julphar's revenue starting in 2025 with accretive impact on profitability in the following years.
The financial period in which the financial impact will appear	Technology Transfer will start in the second half of 2023 with first product launch expected in 2025.

The Name of the Authorized Signatory	IGNACIO ANGELADA
Designation	CFO
Signature and Date	 18.5.23
Company's Seal	